Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to...
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process...
The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process...
05.09.2019
- The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manu...
05.09.2019
- The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manu...
08.08.2019
- In a transaction valued at around $2.4 billion including net debt, US small molecule innovator and API specialist Cambrex has agreed to be acquired by an affiliate of the Permira...
22.11.2018
- Cambrex Corporation, which bills itself as the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has agreed to acquire Avista...
